According to CoinMeta, on November 4th local time, a Swiss company announced that Dalirexen (trade name: Corvex) has been recognized by the U.S. Food and Drug Administration (FDA) as a "breakthrough therapy" for the treatment of insomnia disorders in children and adolescents aged 10 to under 18. Currently, there are no drug treatment options approved by the FDA in the field of childhood insomnia. Last year, Dalirexen was approved for marketing in China for the treatment of adult insomnia patients, and Simcere Pharmaceutical (02096...) currently holds the exclusive rights for the development and commercialization of Dalirexen in the Greater China region.